Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

Crizotinib Impurity 4

Crizotinib Impurity 4 is listed in the pharmaceutical impurity collection under CAS 1233484-06-4. Its represented structure has formula C13H9Cl2FN2O3 and a calculated molecular weight of 331.13 g/mol.

2D chemical structure

O N N + O O - C l F C l ( S )

Chemical identity

Catalog name
Crizotinib Impurity 4
Common name
Crizotinib Impurity 4
Chemical name
3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-2-nitropyridine
CAS
1233484-06-4
SMILES
C[C@H](Oc1cccnc1[N+](=O)[O-])c1c(Cl)ccc(F)c1Cl
InChI
InChI=1S/C13H9Cl2FN2O3/c1-7(11-8(14)4-5-9(16)12(11)15)21-10-3-2-6-17-13(10)18(19)20/h2-7H,1H3/t7-/m0/s1
InChIKey
VGDOUCIQKWTGJY-ZETCQYMHSA-N
Associated API
Crizotinib

Record ID: A4e2b6cc98a5e

Computed properties

C13H9Cl2FN2O3 Molecular formula
331.13 g/molMolecular weight
329.9974 DaMonoisotopic exact mass
65.26 ŲTopological polar surface area
4.5757 Calculated LogP (Wildman–Crippen)
76.3544 cm³/molMolar refractivity (Wildman–Crippen)
4 countHydrogen-bond acceptors
0 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 2 4 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C Cl F H N O 0 3 6 9 12 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight331.1353.48
Calculated LogP (Wildman–Crippen)4.575785.51
Topological polar surface area65.2645.75
Hydrogen-bond acceptors450.68
Hydrogen-bond donors011.28
Rotatable bonds (strict)449.39

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC13H9Cl2FN2O3dimensionless
Molecular weight331.13g/mol
Monoisotopic exact mass329.9974Da
Topological polar surface area65.26Ų
Calculated LogP (Wildman–Crippen)4.5757dimensionless
Molar refractivity (Wildman–Crippen)76.3544cm³/mol
Hydrogen-bond acceptors4count
Hydrogen-bond donors0count
Rotatable bonds (strict)4count
Heavy atoms21count
Heteroatoms8count
Rings2count
Aromatic rings2count
Aliphatic rings0count
Saturated rings0count
Aromatic heterocycles1count
Aliphatic heterocycles0count
Saturated heterocycles0count
Aromatic carbocycles1count
Aliphatic carbocycles0count
Fraction of sp³ carbon atoms0.1538fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters1count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area128.9766Ų
Valence electrons110count
Radical electrons0count
Bertz complexity697.1117index
Balaban J2.375index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for Crizotinib Impurity 4

Qualification and safety assessment of Crizotinib Impurity 4

Explore toxicological qualification of Crizotinib Impurity 4 and ICH M7 mutagenic impurity assessment of Crizotinib Impurity 4 for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for Crizotinib Impurity 4 and acceptable intake and limit justification for Crizotinib Impurity 4. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for Crizotinib Impurity 4

Explore Altox services and software through the Altox Pharma-Hub.